Viral Hepatitis B and C: Screening, Treatment, and Monitoring

Hepatitis B virus (HBV) and hepatitis C virus (HCV) are major causes of chronic liver disease worldwide, representing significant public health challenges with potential for progression to cirrhosis and hepatocellular carcinoma.

[KEY_CONCEPT] Hepatitis B is a DNA virus transmitted through blood, sexual contact, and vertical transmission. Approximately 296 million people worldwide have chronic HBV infection, with highest prevalence in sub-Saharan Africa and East Asia. The risk of chronic infection is inversely related to age at acquisition: >90% of perinatally infected infants develop chronic infection versus <5% of immunocompetent adults.

Hepatitis C is an RNA virus primarily transmitted through blood exposure. An estimated 58 million people have chronic HCV infection globally. In developed countries, injection drug use is the predominant transmission route, while unsafe medical practices remain important in resource-limited settings.

[HIGH_YIELD] Natural History Differences:

• HBV: Can exist in immune-tolerant, immune-active, immune-inactive, and reactivated phases
• HCV: Progresses more predictably, with 15-30% developing cirrhosis over 20-30 years

Risk Factors for Transmission:

[CLINICAL_PEARL] The window period for HCV antibody detection is 2-6 months after infection, during which HCV RNA testing is required for early diagnosis.

[KEY_CONCEPT] Most patients with chronic viral hepatitis are asymptomatic during early stages, making screening programs essential for identification.

Acute Hepatitis Presentation:

• Constitutional symptoms: fatigue, malaise, anorexia, nausea
• Right upper quadrant pain
• Jaundice (occurs in <30% of acute HCV cases)
• Dark urine, clay-colored stools
• Low-grade fever

Chronic Hepatitis Clinical Spectrum:

Asymptomatic → Fatigue/Malaise → Compensated Cirrhosis → Decompensated Cirrhosis ↓ ↓ ↓ ↓ Normal exam Minimal findings Spider angiomata Ascites, jaundice Mild hepatomegaly Mild splenomegaly Encephalopathy Palmar erythema Variceal bleeding

Extrahepatic Manifestations:

[HIGH_YIELD] Hepatitis B Associations:

• Polyarteritis nodosa
• Membranous glomerulonephritis
• Mixed cryoglobulinemia (rare)

[HIGH_YIELD] Hepatitis C Associations:

• Mixed cryoglobulinemia (40-60% of patients)
• Membranoproliferative glomerulonephritis
• Porphyria cutanea tarda
• Lichen planus
• Non-Hodgkin's lymphoma
• Insulin resistance/diabetes

Physical Examination Findings by Stage:

[CLINICAL_PEARL] The presence of extrahepatic manifestations, particularly cryoglobulinemia in HCV, may be the presenting feature that leads to diagnosis of chronic hepatitis.

[KEY_CONCEPT] Diagnosis requires a systematic approach combining serologic markers, viral nucleic acid testing, and assessment of liver injury and fibrosis.

Hepatitis B Diagnostic Algorithm:

Suspected HBV → HBsAg, anti-HBc, anti-HBs ↓ HBsAg Positive → Confirm chronic infection ↓ HBeAg, anti-HBe, HBV DNA quantitative ↓ Assess liver injury: ALT, AST, platelets, INR, albumin ↓ Fibrosis assessment: FIB-4, APRI, or elastography

Hepatitis C Diagnostic Algorithm:

Suspected HCV → HCV antibody ↓ Positive → HCV RNA quantitative ↓ RNA Positive → HCV genotype ↓ Assess liver injury and fibrosis

[HIGH_YIELD] HBV Serologic Interpretation:

Screening Criteria:

[HIGH_YIELD] Universal HBV Screening Recommended:

• All adults ≥18 years (one-time)
• Pregnant women (each pregnancy)
• High-risk populations regardless of age

Universal HCV Screening Recommended:

• All adults 18-79 years (one-time)
• Pregnant women (each pregnancy)
• High-risk populations with periodic testing

Laboratory Monitoring Parameters:

[CLINICAL_PEARL] A single negative HCV antibody test does not rule out infection in immunocompromised patients; HCV RNA testing should be performed if clinical suspicion is high.

[KEY_CONCEPT] Treatment goals differ between HBV (viral suppression, prevent complications) and HCV (cure with sustained virologic response).

Hepatitis B Treatment Indications:

[HIGH_YIELD] Criteria for HBV Treatment Initiation:

• HBeAg-positive: HBV DNA >20,000 IU/mL + ALT >2× ULN
• HBeAg-negative: HBV DNA >2,000 IU/mL + ALT >2× ULN
• Compensated cirrhosis: Any detectable HBV DNA
• Decompensated cirrhosis: Any HBsAg positivity

First-Line HBV Therapies:

HBV Treatment Algorithm:

Confirmed chronic HBV → Assess treatment criteria ↓ Meets criteria → Start first-line therapy (TDF, TAF, or ETV) ↓ Monitor response at 3-6 months ↓ HBV DNA <20 IU/mL → Continue therapy, monitor q6months ↓ Poor response → Check adherence, consider resistance testing

Hepatitis C Treatment:

[HIGH_YIELD] All patients with chronic HCV should be treated unless limited life expectancy (<12 months).

Recommended HCV DAA Regimens:

HCV Treatment Monitoring:

Start DAA therapy → Baseline: CBC, CMP, HCV RNA ↓ Week 4: HCV RNA (optional) ↓ End of treatment: HCV RNA ↓ 12 weeks post-treatment: HCV RNA (SVR12) ↓ SVR12 achieved = CURE

[CLINICAL_PEARL] Drug Interactions: DAA regimens have significant interactions with proton pump inhibitors, anticonvulsants, and rifamycins. Always check interaction databases before prescribing.

Special Populations:

• Pregnancy: HBV treatment with tenofovir is safe; HCV treatment deferred until after delivery
• Renal impairment: Tenofovir AF preferred over DF; sofosbuvir requires dose adjustment
• HIV coinfection: Same treatment principles apply with attention to drug interactions

[KEY_CONCEPT] Long-term monitoring focuses on treatment response, drug resistance, and complications including hepatocellular carcinoma screening.

HBV Monitoring Schedule:

[HIGH_YIELD] HBV Treatment Response Definitions:

• Virologic response: HBV DNA <20 IU/mL
• Biochemical response: ALT normalization
• HBeAg seroconversion: Loss of HBeAg, gain of anti-HBe
• HBsAg loss: Functional cure (rare, <5%)

HCV Post-Treatment Surveillance:

SVR12 achieved → Annual monitoring if cirrhosis ↓ ↓ No cirrhosis → Discharge to primary care ↓ Circhosis → Continue HCC surveillance + varices screening

Hepatocellular Carcinoma Surveillance:

[HIGH_YIELD] HCC Screening Indications:

• HBV: All cirrhotic patients; non-cirrhotic patients >40 years, family history HCC, or African origin >20 years
• HCV: All patients with advanced fibrosis (≥F3) regardless of treatment status

HCC Surveillance Protocol:

• Imaging: Ultrasound every 6 months
• Biomarker: AFP every 6 months (optional, not required)
• High-risk patients: Consider MRI if inadequate ultrasound visualization

Resistance Monitoring:

For HBV patients with suboptimal response:

• Check adherence first
• Resistance testing if HBV DNA >1,000 IU/mL after ≥6 months of therapy
• Switch to alternative high-barrier agent if resistance confirmed

Laboratory Monitoring Schedule:

[CLINICAL_PEARL] Reactivation Risk: Patients with resolved HBV (anti-HBc positive, HBsAg negative) require monitoring and potential prophylaxis when receiving immunosuppressive therapy, chemotherapy, or anti-CD20 monoclonal antibodies.

Drug Safety Monitoring:

• Tenofovir DF: Monitor creatinine, phosphorus, bone density
• Tenofovir AF: Preferred in patients with bone/kidney concerns
• DAA therapy: Generally well-tolerated, minimal monitoring required

[KEY_CONCEPT] Both HBV and HCV can progress to cirrhosis and hepatocellular carcinoma, but outcomes differ significantly between treated and untreated patients.

Progression to Cirrhosis:

Hepatocellular Carcinoma Risk:

[HIGH_YIELD] Annual HCC Incidence:

• HBV cirrhosis: 2-5% per year
• HCV cirrhosis: 1-4% per year
• HBV non-cirrhotic: 0.2-0.6% per year (varies by population)
• HCV post-SVR cirrhosis: 0.33-1.67% per year

Decompensated Cirrhosis Manifestations:

Compensated Cirrhosis ↓ First Decompensation Event ↓ ┌─────────────┬─────────────┬─────────────┬─────────────┐ │ Ascites │ Varices │ Encephalopathy│ Jaundice │ │ (most │ bleeding │ │ │ │ common) │ │ │ │ └─────────────┴─────────────┴─────────────┴─────────────┘

Prognosis by Treatment Status:

[HIGH_YIELD] HBV Treatment Outcomes:

• Virologic response: 80-90% achieve HBV DNA <20 IU/mL
• HBeAg seroconversion: 20-30% over 5 years
• HBsAg loss: <5% over 5 years (higher in genotype A)
• Cirrhosis regression: Possible with sustained viral suppression

HCV Treatment Outcomes:

• SVR12 rates: >95% with DAA therapy
• SVR = cure: No further HCV transmission risk
• Cirrhosis benefits: Reduced HCC risk, improved liver function
• Extrahepatic benefits: Resolution of cryoglobulinemia, improved insulin resistance

Risk Stratification Models:

Special Complications:

[CLINICAL_PEARL] HBV Reactivation: Risk factors include:

• Anti-CD20 therapy (rituximab): 10-60% reactivation risk
• Chemotherapy: 5-50% depending on regimen
• High-dose corticosteroids: Variable risk
• Anti-TNF therapy: Low risk but monitor

Long-term Prognosis Factors:

Favorable Prognosis:

• Early treatment initiation
• Sustained viral response (HCV) or suppression (HBV)
• Absence of cirrhosis at treatment start
• No alcohol use
• Younger age
• Female gender

Poor Prognosis:

• Decompensated cirrhosis
• HCC development
• Treatment non-response or relapse
• Continued alcohol use
• HIV or HDV coinfection

[HIGH_YIELD] Post-SVR HCV Outcomes:

• Overall survival improvement
• Reduced liver-related mortality
• Decreased need for liver transplantation
• Resolution of most extrahepatic manifestations
• Persistent but reduced HCC risk if cirrhotic